Meet the New Nasdaq-100 Stock That’s Crushing Nvidia, Micron, and Sandisk. Is It Too Late to Buy?
This stock has soared more than 600% this year.
The latest NASDAQ-100 stock to surpass Nvidia, Micron, and SanDisk is Moderna (MRNA), surging over 600% this year. While AI stocks continue to grow, investors have diversified into other industries, highlighting new growth prospects. Moderna, once a vaccine pioneer, now expands into oncology and rare disease treatments. After a year of setbacks, Moderna regained momentum post-pandemic, cutting costs and securing approvals for new products.
Its oncology-focused pipeline, particularly the intismeran autogene cancer vaccine, holds promise for future revenue. Currently trading near $225, surpassing Wall Street's price target of $122, Moderna presents a compelling opportunity, but investors should monitor it for potential dips to capitalize on its continued growth.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
